Immunology:
Unlocking the adaptive immune system

The adaptive immune system, with its remarkable specificity and memory, is central to our defense against pathogens and a key target for novel therapeutic interventions in areas like cancer, autoimmunity, and infectious diseases. At OHMX.bio, we provide advanced omics solutions to deeply characterize immune responses, unravel cellular diversity, and accelerate the development of precision immunotherapies. Our expertise empowers researchers and clinicians with comprehensive insights into the intricate world of immunology.
Contact our experts

Advanced omics for comprehensive immune profiling

Understanding the complexities of immune recognition and response requires high-resolution molecular analysis. OHMX.bio offers a specialized suite of services designed to meet the critical needs of immunology research:

HLA Typing

The Human Leukocyte Antigen (HLA) system plays a pivotal role in immune recognition and is critical for transplantation, vaccine development, and understanding disease susceptibility. OHMX.bio leverages advanced sequencing technologies, particularly long-read sequencing, to provide high-resolution HLA typing. This approach resolves complex HLA loci with unparalleled accuracy, crucial for precise matching in transplantation and for identifying genetic predispositions to immune-mediated diseases.
The immunopeptidome comprises the specific set of peptides displayed by HLA molecules, acting as the ultimate signals for T-cell surveillance and activation. OHMX.bio utilizes advanced proteomic workflows to directly identify and quantify these MHC-associated peptides  (both Class I and II) with high sensitivity. This direct profiling is instrumental for the discovery of tumor-specific neoantigens, the development of personalized cancer vaccines, and the precise validation of therapeutic targets.

TCR/BCR Sequencing

T-cell receptors (TCRs) and B-cell receptors (BCRs) are the unique molecular identifiers of adaptive immune cells, dictating their antigen specificity. We offer comprehensive TCR and BCR sequencing services, at both bulk and single-cell resolution, to profile immune repertoire diversity, track clonal expansions, and investigate immune responses in various disease contexts, including immuno-oncology, autoimmune disorders, and infectious diseases.

Isoform Detection & Analysis

Gene isoforms, arising from alternative splicing, significantly expand the functional diversity of the proteome and play critical roles in immune cell development, activation, and function. OHMX.bio utilizes long-read RNA sequencing to characterize full-length transcripts, enabling unambiguous identification and quantification of splice variants and fusion transcripts. This provides a more complete picture of gene expression and its impact on immune processes.

Contact our experts
OHMX.bio - Innovative omics solutions

Case studies

Case study 1: High-resolution HLA typing for large-scale cohorts

Accurate and scalable HLA typing is essential for managing large donor registries, biobanks, and for rapid assessment of acute patient samples. Traditional methods can be expensive, slow, and logistically challenging.
In a study titled “Cost-Effective and Highly Scalable Typing of HLA Classes I and II Genes of up to 96 Individuals Using Nanopore Sequencing” by Steven Verbruggen et al. (PMID: 38654300), OHMX.bio demonstrated a groundbreaking solution. This innovative approach enables HLA typing from 1 to 96 individuals simultaneously using a targeted PCR and Native Barcoding kit from Oxford Nanopore Technologies. The core point of this study was to prove that rapid, low-cost, and highly accurate HLA typing is achievable at scale, making it highly relevant for large-scale HLA typing projects and significantly accelerating research and clinical applications. The entire process, from DNA to HLA typing result, can be completed within 5.5 to 10.5 hours depending on sample numbers, with data analysis taking only 1 to 5 minutes per sample. This demonstrates OHMX.bio’s capability to deliver precise and efficient HLA typing solutions for diverse immunological studies.

Case study 2: Isoform detection reveals functional non-coding mutations in melanoma

The complexity of gene expression, particularly alternative splicing, means that mutations previously considered non-coding can have significant functional consequences. Understanding these nuances is crucial in cancer immunology, where subtle genetic changes can impact immune recognition and therapeutic response.
In a recent study (“Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma,” Pepe et al., 2025), researchers, including those from OHMX.bio, demonstrated the importance of integrating DNA and RNA sequencing data for accurate mutation annotation. The study revealed that a significant portion of mutations previously annotated as coding in melanoma were, in fact, non-coding due to the use of non-expressed reference transcripts. Specifically, mutations in the shared promoter region of IRF3 and BCL2L12 were found to downregulate their expression, leading to decreased TP53 levels and poorer responses to immunotherapy. This highlights how misannotated non-coding mutations in promoter regions can have functional consequences, affecting gene expression and patient response to therapy [PMID: 40359938]. This work underscores OHMX.bio’s expertise in isoform detection and its critical role in uncovering previously overlooked functional mutations, providing deeper insights into immune-related diseases like cancer.
Contact our experts

Partner with OHMX.bio for your immunology research

OHMX.bio is committed to advancing immunology research through cutting-edge omics technologies and expert bioinformatics. Our dedication to scientific excellence, precision, and rapid turnaround times ensures that you receive the highest quality data and actionable insights. Collaborate with OHMX.bio to accelerate your understanding of immune responses, identify novel therapeutic targets, and drive the development of personalized immunotherapies.
OHMX.bio_Innovative omics solutions_Tailored Personal Approach

Let’s get in touch!

Are you curious about how we can work on your -omics challenges together? Fill out the form below!
Our experts will reply within 2 working days to freely discuss your omics project.

Our publications using our cell en gene therapies

  1.  
OHMX..bio logo
Your partner for innovative OMICS solutions.
Linkedin Google
OHMX.bio is part of
the anacura group.
© 2026 OHMX.bio

Proudly created by DauntlessDonkey

TESTING SERVICES

EXPERTISE

OHMX.bio

CONTACT

  • Belgium
    Noorwegenstraat 4
    9940 Evergem
  • Switzerland
    Phenyl - 2nd floor, Route de la Corniche 3, 1066 Epalinges
Oxford Nanopore Service Certified
logo-cir
Registered supplier logo_Scientist.com